SCHEMBL2745951

SCHEMBL2745951

Cc1cc(C(=O)NN)cc(Cl)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
KDM4E B2RXH2 6/20 0.49
GAA P10253 5/20 0.49
PTGES O14684 1/20 0.44
ALOX5 P09917 1/20 0.44
MAPT P10636 3/20 0.44
POLB P06746 3/20 0.44
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NSD2 O96028 1/20 0.44
ALPL P05186 1/20 0.44
ALPI P09923 1/20 0.44
ALPG P10696 1/20 0.44
APEX1 P27695 1/20 0.44
HTT P42858 1/20 0.44
RECQL P46063 1/20 0.44
BLM P54132 1/20 0.44
CASP6 P55212 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MPO P05164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6402681 0.87 KDM4E (0.52) ALDH1A1KDM4EGAAMAPTPOLB
SCHEMBL1178795 0.87 KDM4E (0.52) ALDH1A1KDM4EGAAMAPTPOLB
Hydrochloric Acid SCHEMBL1425649 0.85 KDM4E (0.50) ALDH1A1KDM4EGAAMAPTPOLB
SCHEMBL21383742 0.84 SLC6A3 (0.43) ALDH1A1PTGESALOX5L3MBTL1SLC6A3
SCHEMBL30737501 0.84 SLC6A3 (0.43) ALDH1A1PTGESALOX5L3MBTL1SLC6A3
SCHEMBL26624247 0.84 SLC6A3 (0.43) ALDH1A1PTGESALOX5POLBLMNA
SCHEMBL13702406 0.83 BRD4 (0.44) ALDH1A1PTGESALOX5POLBL3MBTL1
SCHEMBL583717 0.79 POLB (0.52) ALDH1A1PTGESALOX5POLBLMNA
SCHEMBL8072495 0.79 POLB (0.41) ALDH1A1PTGESALOX5MAPTPOLB
SCHEMBL18814856 0.79 SMN1; SMN2 (0.54) ALDH1A1KDM4EMAPTPOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025109540-A1 MACROCYCLIC COMPOUNDS AS KIF18A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2025-05-30 WO disclosed
US-20160304506-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-10-20 US disclosed
US-20160304506-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-10-20 US disclosed
US-20160304506-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-10-20 US disclosed
US-9399638-B2 Substituted pyridine compounds as CRAC modulators LUPIN LIMITED (IN) 2016-07-26 US disclosed
US-9399638-B2 Substituted pyridine compounds as CRAC modulators LUPIN LIMITED (IN) 2016-07-26 US disclosed
US-9399638-B2 Substituted pyridine compounds as CRAC modulators LUPIN LIMITED (IN) 2016-07-26 US disclosed
US-20150111900-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2015-04-23 US disclosed
US-20150111900-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2015-04-23 US disclosed
US-20150111900-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2015-04-23 US disclosed
CN-101370805-A Novel pyridine derivatives ACTELION PHARMACEUTICALS LTD (CH) 2009-02-18 CN disclosed
US-20090005421-A1 Novel Pyridine Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2009-01-01 US disclosed
EP-1979345-A2 NOVEL PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-10-15 EP disclosed
US-20070185100-A1 Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-08-09 US disclosed
WO-2007086001-A2 NOVEL PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2007-08-02 WO disclosed
CN-1918154-A Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists NPS PHARMA INC (SE) 2007-02-21 CN disclosed
EP-1716143-A1 POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AstraZeneca AB (SE) 2006-11-02 EP disclosed
WO-2006057945-A2 2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2006-06-01 WO disclosed
US-20060025414-A1 Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2006-02-02 US disclosed
WO-2005080386-A1 POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS ASTRAZENECA AB (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111900-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS ORAI1, RYR2, RYR1 ALDH1A1 2188/4885KDM4E 2333/4885GAA 1155/4885
US-20060025414-A1 Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists GRM3, GRM1, GRM4 ALDH1A1 3756/4885KDM4E 2508/4885GAA 3233/4885
US-20090005421-A1 Novel Pyridine Derivatives NFATC1, TPMT, CD47 ALDH1A1 2426/4885KDM4E 708/4885GAA 3502/4885
US-20160304506-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS ORAI1, RYR2, RYR1 ALDH1A1 2188/4885KDM4E 2333/4885GAA 1155/4885
US-20070185100-A1 Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists GRM3, GRM1, GRM4 ALDH1A1 3616/4885KDM4E 2582/4885GAA 3016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.